WVE - wavelifesciences.com Operating income before deduction of amortization
Wave Life Sciences relies on unique RNA stereopurity technology to capture the precision medicine market. EBITDA dynamics confirm this resilience, with the metric standing at 0.00. Business development is supported by a strategic alliance with GSK and strict FDA oversight, while drug delivery is ensured by a high-tech cold chain with continuous monitoring.
Summary analytical data breakdowns for Wave Life Sciences Ltd. (WVE)
- stock price and consensus target price:
- market capitalization statistics:
- balance sheet equity data:
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Wave Life Sciences|WVE - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient Wave Life Sciences Ltd|WVE - Company Aggregate Debts|Debt to Book Value Wave Life Sciences|WVE - Company Long-Term Debts|Short-Term Debt Volume Wave Life Sciences|Immediate Liquidity wavelifesciences.com
- earnings and valuation multiples information:
WVE - Company Net Income|Net Profit Forecast Wave Life Sciences|WVE - P/E Multiple|Projected Price to Earnings wavelifesciences.com|WVE - PEG Multiple|Company Value to EBITDA Wave Life Sciences|WVE - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Wave Life Sciences|WVE - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months wavelifesciences.com|WVE - Net earnings per share growth this year|Net earnings per share growth forecast for next year Wave Life Sciences
Summary company analytics:WVE - Wave Pharma
To objectively assess the operational efficiency of Wave Life Sciences (WVE), investors must analyze the actual cash flow from core operations. This volume of earnings before interest, taxes, depreciation, and amortization excludes non-cash charges, allowing for the identification of the true long-term profitability trend. The metric measures the business's ability to generate cash before accounting for debt and tax obligations. For an RNA-drug developer, this indicator is critical for controlling R&D costs. The stability of this figure confirms the resilience of financial reserves while awaiting clinical trial results.
Who Wave Life Sciences competes with
Tempus - Profit before payment of interest, taxes and amortization|Qiagen N.V. - Operating profit EBITDA|Operating income before deduction of amortization ionispharma.com IONS|RGEN: Operating profit EBITDA|Profit before deduction of interest, taxes, depreciation and amortization RNA (Avidity Biosciences Inc)|CRSP (CRISPR Therapeutics Corp) - Operating profit EBITDA|Profit before interest, taxes and amortization GeneDx Corp WGS|Operating profit before deduction of amortization RARE (Ultragenyx Pharmaceutical)|BEAM (beamtx.com) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Sarepta SRPT|Operating income before deduction of amortization Twist Bioscience Inc (TWST)|10x Genomics Corp - Operating profit EBITDA|Intellia Corp (NTLA) - Operating profit before deduction of amortization|STOK: Operating profit EBITDA|BLFS - Operating income before deduction of amortization|MAZE (Maze Therapeutics) - Operating profit EBITDA|Profit before interest, taxes and amortization Sionna Therapeutics, Inc. SION|Profit before payment of interest, taxes and amortization Prime Medicine Corp (PRME)|Taysha Corp - Operating profit before amortization|Operating profit EBITDA QURE (uniQure N.V.)|MGTX - Operating profit before deduction of amortization|REGENXBIO - Operating profit EBITDA|Profit before interest, taxes and amortization Solid Biosciences Inc|Ocugen Corp (OCGN) - Profit before payment of interest, taxes and amortization|PACB - Operating income before deduction of amortization|Operating profit before deduction of amortization BNTC|Operating profit before deduction of amortization designtx.com (DSGN)|Operating profit before deduction of amortization RCKT (Rocket Pharmaceuticals, Inc.)|Profit before payment of interest, taxes and amortization FDMT (4DMT)|Operating profit EBITDA LXEO (Lexeo Therapeutics, Inc.)|Korro Bio Inc. (KRRO) - Profit before interest, taxes and amortization|Editas Medicine, Inc. - Operating profit EBITDA|SLN (silence-therapeutics.com) - Operating profit before amortization|proqr.com (PRQR) - Profit before payment of interest, taxes and amortization|Operating profit before amortization CDXS|SGMO (Sangamo) - Operating profit EBITDA|Operating profit EBITDA Nautilus Biotechnology Inc|Operating profit before deduction of amortization MGX (Metagenomi, Inc.)|Operating profit before deduction of amortization precisionbiosciences.com DTIL|Operating profit EBITDA GBIO (Generation Bio)|Operating profit EBITDA Boundless Bio Inc. BOLD|XCUR: Operating profit before deduction of amortization|IMNN: Profit before payment of interest, taxes and amortization|PHIO: Operating profit EBITDA|Profit before interest, taxes and amortization Mustang Bio (MBIO)|Operating profit before deduction of amortization RNAZ|BNGO: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Applied DNA (APDN)|Profit before payment of interest, taxes and amortization BLUE (bluebird bio, Inc)|Operating profit EBITDA IPA (ImmunoPrecise Antibodies Ltd.)|Operating income before deduction of amortization omegatherapeutics.com (OMGA)|Singular Genomics - Operating profit EBITDA|Profit before deduction of interest, taxes, depreciation and amortization RGLS|SYRS: Operating profit EBITDA|Profit before interest, taxes and amortization Telesis Bio, Inc (TBIO)|Operating profit before deduction of amortization TCON|UBX: Income before deduction of interest, taxes and amortization
